AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Okta CRO Addison James sells 7867 shares at varying prices.
ByAinvest
Wednesday, Jul 16, 2025 5:10 pm ET1min read
Okta, Inc. (OKTA) has announced that Addison Jonathan James, Chief Revenue Officer, has recently engaged in a series of transactions involving the sale of shares. Specifically, he sold 2863 shares at $91.78 per share on July 14, 2025, 3164 shares at $92.21 per share on July 14, 2025, 2500 shares at $91.7 per share on July 15, 2025, and 500 shares at $92.39 per share on July 15, 2025.
Okta Inc. (OKTA) has recently experienced insider trading activity involving its Chief Revenue Officer, Jonathan James Addison. Addison has sold a total of 8,427 shares of Okta stock over two days, with the transactions occurring on July 14 and 15, 2025.On July 14, Addison sold 2,863 shares at $91.78 per share and an additional 3,164 shares at $92.21 per share. The following day, he sold 2,500 shares at $91.70 per share and 500 shares at $92.39 per share. The total proceeds from these transactions were $914,775.00.
Okta's Form 144 filing indicates that Addison sold the shares under a Rule 10b5-1 trading plan, which is a pre-arranged plan that allows insiders to sell shares without violating insider trading rules. The filing also notes that the shares were acquired as restricted stock units (RSUs) on December 15, 2023.
The market impact of these transactions is expected to be minimal. Given the small size of the transactions relative to Okta's total shares outstanding, the sales are unlikely to significantly affect the company's stock price. Furthermore, the pre-arranged nature of the sales suggests that Addison's actions are part of a routine liquidity or tax-planning strategy rather than a sign of a broader change in the company's outlook.
Investors should monitor these transactions for sentiment cues, but the data suggests a controlled diversification rather than a strategic shift. The use of a Rule 10b5-1 plan indicates adherence to best-practice governance and reduces the risk of trading on non-public information.
References:
[1] https://www.stocktitan.net/sec-filings/HIMS/form-4-hims-hers-health-inc-insider-trading-activity-994e318fa5d9.html
[2] https://smestreet.in/technology/okta-palo-alto-boost-threat-response-with-new-integrations-9502984
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet